Non-Invasive Evaluation of NASH and Advanced Fibrosis

Non-Invasive Evaluation of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis: Present and Future The current, but imperfect, gold standard for diagnosis of NASH fibrosis is the liver biopsy. While liver biopsy allows pathologists to directly observe liver tissue, its utility in both clinical trials and clinical practice is limited. For example, in clinical development, primary endpoint data relies on just a small portion of the liver and is subject to sampling and central reader variability. In clinical practice, the invasive, costly and potentially painful and risky biopsy procedure is unlikely to gain widespread acceptance and use in the routine diagnosis of NASH fibrosis. With several therapeutics expected to reach the market soon, there is an urgent need to develop non-invasive biomarkers for the identification of patients at high risk for NASH fibrosis to ensure the right patients get the right treatment, at the right time. While there is no shortage of promising blood- and imaging-based biomarker leads, the application of a non-invasive biomarker in NASH is still largely under development. With the potential to revolutionize clinical trial design and patient access to new treatments, the race is on to find markers that not only have diagnostic potential but prognostic and treatment-monitoring utility. This expert-led webinar will review the most promising biomarkers for NASH fibrosis including their performance, advantages and limitations in both clinical development and in daily clinical practice.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/videos/Webinar_Non-Invasive-Evaluation-of-NASH-and-Advanced-Fibrosis_March-2020.jpg